Rodrigo Sánchez-Bayona, Alfonso Lopez de Sa, Yolanda Jerez Gilarranz, Ana Sanchez de Torre, Manuel Alva, Isabel Echavarria, Fernando Moreno, Pablo Tolosa, Blanca Herrero Lopez, Alicia de Luna, Laura Lema, Salvador Gamez Casado, Ainhoa Madariaga, Sara López-Tarruella, Luis Manso, Coralia Bueno-Muiño, Jose A Garcia-Saenz, Eva Ciruelos, Miguel Martin
PURPOSE: Everolimus in combination with endocrine therapy (ET) was formerly approved as 2nd-line therapy in HR(+)/HER2(-) advanced breast cancer (aBC) patients (pts) progressing during or after a non-steroidal aromatase inhibitor (NSAI). Since this approval, the treatment landscape of aBC has changed dramatically, particularly with the arrival of CDK 4-6 inhibitors. Endocrine monotherapy after progression to CDK4/6 inhibitors has shown a limited progression-free survival (PFS), below 3 months...
May 4, 2024: Breast Cancer Research and Treatment